Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759
RLT
0.75
134.4%
88E
0.001
-50%
H2G
0.006
100%
NRZ
0.001
-50%
WOA
0.029
61.1%
TOU
0.008
-46.7%
PR2
0.079
33.9%
ALM
0.003
-40%
CTN
0.004
33.3%
CKA
0.036
-40%
BEZ
0.037
32.1%
ANR
0.007
-36.4%
STN
0.255
27.5%
DTM
0.004
-33.3%
SHO
0.028
27.3%
ECT
0.002
-33.3%
MLX
0.665
26.7%
NTM
0.002
-33.3%
AGR
0.049
25.6%
PUA
0.007
-30%
SMX
0.049
25.6%
OVT
0.005
-28.6%
AZY
0.47
25.3%
ID8
0.008
-27.3%
ADG
0.005
25%
CYB
0.073
-27%
LEG
0.01
25%
SLH
1.54
-22.2%
NMG
0.015
25%
OEC
0.09
-21.7%
VMC
0.12
25%
SNX
0.018
-21.7%
WSR
0.01
25%
RML
0.011
-21.4%
RWL
0.28
24.4%
RMS
2.2
-21.1%
EGR
0.155
24%
BSX
0.057
-20.8%
PSC
0.105
23.5%
CUE
0.1
-20%
